comparemela.com

Edesa Biotech (NASDAQ:EDSA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Brookline Capital Management in a research report issued on Thursday, Benzinga reports. They currently have a $57.00 price target on the stock. Separately, HC Wainwright decreased their price target on shares of Edesa Biotech from $112.00 to […]

Related Keywords

,Millennium Management ,Cibc World Market Inc ,Cm Management ,Renaissance Technologies ,Edesa Biotech Inc ,Edesa Biotech ,Get Free Report ,Brookline Capital Management ,World Market ,Edesa Biotech Daily ,Nasdaq Edsa ,Redsa ,Medical ,Reiterated Rating ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.